168 related articles for article (PubMed ID: 37861217)
21. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders.
Herold KC; Gitelman SE; Ehlers MR; Gottlieb PA; Greenbaum CJ; Hagopian W; Boyle KD; Keyes-Elstein L; Aggarwal S; Phippard D; Sayre PH; McNamara J; Bluestone JA;
Diabetes; 2013 Nov; 62(11):3766-74. PubMed ID: 23835333
[TBL] [Abstract][Full Text] [Related]
22. Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years.
Herold KC; Gitelman S; Greenbaum C; Puck J; Hagopian W; Gottlieb P; Sayre P; Bianchine P; Wong E; Seyfert-Margolis V; Bourcier K; Bluestone JA;
Clin Immunol; 2009 Aug; 132(2):166-73. PubMed ID: 19443276
[TBL] [Abstract][Full Text] [Related]
23. Liraglutide in Children and Adolescents with Type 2 Diabetes.
Tamborlane WV; Barrientos-Pérez M; Fainberg U; Frimer-Larsen H; Hafez M; Hale PM; Jalaludin MY; Kovarenko M; Libman I; Lynch JL; Rao P; Shehadeh N; Turan S; Weghuber D; Barrett T;
N Engl J Med; 2019 Aug; 381(7):637-646. PubMed ID: 31034184
[TBL] [Abstract][Full Text] [Related]
24. Baricitinib and β-Cell Function in Patients with New-Onset Type 1 Diabetes.
Waibel M; Wentworth JM; So M; Couper JJ; Cameron FJ; MacIsaac RJ; Atlas G; Gorelik A; Litwak S; Sanz-Villanueva L; Trivedi P; Ahmed S; Martin FJ; Doyle ME; Harbison JE; Hall C; Krishnamurthy B; Colman PG; Harrison LC; Thomas HE; Kay TWH;
N Engl J Med; 2023 Dec; 389(23):2140-2150. PubMed ID: 38055252
[TBL] [Abstract][Full Text] [Related]
25. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
26. Closed-Loop Therapy and Preservation of C-Peptide Secretion in Type 1 Diabetes.
Boughton CK; Allen JM; Ware J; Wilinska ME; Hartnell S; Thankamony A; Randell T; Ghatak A; Besser REJ; Elleri D; Trevelyan N; Campbell FM; Sibayan J; Calhoun P; Bailey R; Dunseath G; Hovorka R;
N Engl J Med; 2022 Sep; 387(10):882-893. PubMed ID: 36069870
[TBL] [Abstract][Full Text] [Related]
27. Treatment of new-onset type 1 diabetes with peptide DiaPep277 is safe and associated with preserved beta-cell function: extension of a randomized, double-blind, phase II trial.
Raz I; Avron A; Tamir M; Metzger M; Symer L; Eldor R; Cohen IR; Elias D
Diabetes Metab Res Rev; 2007 May; 23(4):292-8. PubMed ID: 17124720
[TBL] [Abstract][Full Text] [Related]
28. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.
Keymeulen B; Vandemeulebroucke E; Ziegler AG; Mathieu C; Kaufman L; Hale G; Gorus F; Goldman M; Walter M; Candon S; Schandene L; Crenier L; De Block C; Seigneurin JM; De Pauw P; Pierard D; Weets I; Rebello P; Bird P; Berrie E; Frewin M; Waldmann H; Bach JF; Pipeleers D; Chatenoud L
N Engl J Med; 2005 Jun; 352(25):2598-608. PubMed ID: 15972866
[TBL] [Abstract][Full Text] [Related]
29. A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes.
Keymeulen B; van Maurik A; Inman D; Oliveira J; McLaughlin R; Gittelman RM; Roep BO; Gillard P; Hilbrands R; Gorus F; Mathieu C; Van de Velde U; Wisniacki N; Napolitano A
Diabetologia; 2021 Feb; 64(2):313-324. PubMed ID: 33145642
[TBL] [Abstract][Full Text] [Related]
30. Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomized, double-blind phase II trials.
Schloot NC; Meierhoff G; Lengyel C; Vándorfi G; Takács J; Pánczél P; Barkai L; Madácsy L; Oroszlán T; Kovács P; Sütö G; Battelino T; Hosszufalusi N; Jermendy G
Diabetes Metab Res Rev; 2007 May; 23(4):276-85. PubMed ID: 17103487
[TBL] [Abstract][Full Text] [Related]
31. Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals.
Sims EK; Bundy BN; Stier K; Serti E; Lim N; Long SA; Geyer SM; Moran A; Greenbaum CJ; Evans-Molina C; Herold KC;
Sci Transl Med; 2021 Mar; 13(583):. PubMed ID: 33658358
[TBL] [Abstract][Full Text] [Related]
32. Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.
Aronson R; Gottlieb PA; Christiansen JS; Donner TW; Bosi E; Bode BW; Pozzilli P;
Diabetes Care; 2014 Oct; 37(10):2746-54. PubMed ID: 25011949
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
Dejgaard TF; Frandsen CS; Hansen TS; Almdal T; Urhammer S; Pedersen-Bjergaard U; Jensen T; Jensen AK; Holst JJ; Tarnow L; Knop FK; Madsbad S; Andersen HU
Lancet Diabetes Endocrinol; 2016 Mar; 4(3):221-232. PubMed ID: 26656289
[TBL] [Abstract][Full Text] [Related]
34. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
Heise T; Mari A; DeVries JH; Urva S; Li J; Pratt EJ; Coskun T; Thomas MK; Mather KJ; Haupt A; Milicevic Z
Lancet Diabetes Endocrinol; 2022 Jun; 10(6):418-429. PubMed ID: 35468322
[TBL] [Abstract][Full Text] [Related]
35. High proinsulin:C-peptide ratio identifies individuals with stage 2 type 1 diabetes at high risk for progression to clinical diagnosis and responses to teplizumab treatment.
Sims EK; Geyer SM; Long SA; Herold KC
Diabetologia; 2023 Dec; 66(12):2283-2291. PubMed ID: 37667106
[TBL] [Abstract][Full Text] [Related]
36. Teplizumab: promises and challenges of a recently approved monoclonal antibody for the prevention of type 1 diabetes or preservation of residual beta cell function.
Fanaropoulou NM; Tsatsani GC; Koufakis T; Kotsa K
Expert Rev Clin Immunol; 2024 Feb; 20(2):185-196. PubMed ID: 37937833
[TBL] [Abstract][Full Text] [Related]
37. Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes.
Long SA; Thorpe J; Herold KC; Ehlers M; Sanda S; Lim N; Linsley PS; Nepom GT; Harris KM
Cell Immunol; 2017 Sep; 319():3-9. PubMed ID: 28844471
[TBL] [Abstract][Full Text] [Related]
38. Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes.
Garg SK; Henry RR; Banks P; Buse JB; Davies MJ; Fulcher GR; Pozzilli P; Gesty-Palmer D; Lapuerta P; Simó R; Danne T; McGuire DK; Kushner JA; Peters A; Strumph P
N Engl J Med; 2017 Dec; 377(24):2337-2348. PubMed ID: 28899222
[TBL] [Abstract][Full Text] [Related]
39. No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes.
Walter M; Philotheou A; Bonnici F; Ziegler AG; Jimenez R;
Diabetes Care; 2009 Nov; 32(11):2036-40. PubMed ID: 19690081
[TBL] [Abstract][Full Text] [Related]
40. The Deterrence of Rapid Metabolic Decline Within 3 Months After Teplizumab Treatment in Individuals at High Risk for Type 1 Diabetes.
Sims EK; Cuthbertson D; Herold KC; Sosenko JM
Diabetes; 2021 Dec; 70(12):2922-2931. PubMed ID: 34551936
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
